The Sanos Board of Directors provides strategic oversight and supports long-term value creation. With diverse experience from the life sciences industry, clinical research, finance, and governance, the board ensures that Sanos remains focused, responsible, and well-positioned for future growth.
Sebastian has an International BSc and MSc in Finance with a sub-degree in Japanese, from the University of Gothenburg School of Business, Economics and Law in Sweden.
Sebastian Inger joined InvestCorp in 2013. Prior to InvestCorp he worked in the industrial team at Credit Suisse in London. Previously he worked at Swedbank in Sweden, in both the equity research team and corporate finance division.
Sebastian has been the Board Director for Sanos since December 2020 and is also currently sitting on the boards of Cambio Healthcare Systems, Abax and Georg Jensen.
Henning is the former CFO of Sanos and was with the company from 2021-2024. He holds a master’s degree in Business Economics and Auditing from University of Copenhagen, Denmark.
Henning is a senior finance executive who has served as CFO in both public and private companies in several countries in Europe, UK and in the US. At Sanos, he was responsible for all disciplines within finance, tax, treasury, accounting etc.
Anders Faeste joined The Boston Consulting Group in 2005. He leads BCG’s Health Care practice in the Nordics. He was chosen to be a BCG Ambassador in Washington in 2009. Anders has supported companies in the life science and health care industries across the value chain, and he is a topic expert focused primarily on commercial topics.
His dual interests in the life sciences industry and commercial topics have made Anders a valuable member of teams working on a wide range of projects, including growth strategies, commercial excellence, pricing, innovation excellence, and reorganizations. He supports leading global companies across the pharma and medtech industries.
Anders contributed to the BCG report The Need to Transform the Medtech Model in Europe.
Prior to joining BCG, Anders worked as the head of marketing at APMM.
Pierre Khaitrine joined Investcorp in 2019. Prior to that, he was a member of the Consumer & Retail team at Credit Suisse in London.
Pierre holds an MSc in Management from EMLYON Business School
Andrea joined Investcorp in 2014. Prior to that she held the role of CFO at TDX Group – sold by Investcorp in January 2014. Before this role she was CEO – EMEA at Fellowes, a privately owned US manufacturing company. Earlier roles include the CFO at Willett International (a global print technology company), Head of Corporate Strategy for BAA and various roles at Ernst & Young, Price Waterhouse and J.P.Morgan.
Andrea received a B.Sc in Electronics and a MBA from London Business School. Andrea holds the FCA Senior Management Function 3 (Executive Director).
Jeppe is the CEO of NBCD, as well as the Group CEO of Sanos (the parent company of NBCD, Neuroscios, Blueskin and Sanos Clinic).
Jeppe holds a master’s in Pharmaceutical Science (M.Sc. Pharm) from University of Copenhagen, Denmark, and joined Nordic Bioscience in 2007 as a CRA. In 2010 he became Head of Clinical Development in 2010, and in 2014 he transitioned into his position as the CEO of NBCD.
Jeppe has been involved on an operational and executive level in numerous clinical studies with more than 18,000 patients within various therapeutic fields but primarily within osteoporosis and osteoarthritis leading to market approved drugs in both indications. Jeppe has been spearheading the journey of building Sanos from a handful of people back in 2006 to the 250 employees’ midsize multi-niche CRO company of 2025.
With his history of success in building and growing organizations, his strong expertise from both CRO and Investigator perspective, and his in-depth project leadership in clinical development, he has an ability to identify market trends and conceptualize strategies with an aim of innovation to improve work and business processes.